Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) ROE %: 0.00% (As of . 20)


What is Pharmedic Pharmaceutical Medicinal Joint Stock Company ROE %?

Pharmedic Pharmaceutical Medicinal Joint Stock Company HSTC:PMC ROE % is 0.00% as of . 20.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Pharmedic Pharmaceutical Medicinal Joint Stock Company's annualized net income for the quarter that ended in . 20 was ₫ Mil. Pharmedic Pharmaceutical Medicinal Joint Stock Company's average Total Stockholders Equity over the quarter that ended in . 20 was ₫ Mil. Therefore, Pharmedic Pharmaceutical Medicinal Joint Stock Company's annualized ROE % for the quarter that ended in . 20 was %.

The historical rank and industry rank for Pharmedic Pharmaceutical Medicinal Joint Stock Company's ROE % or its related term are showing as below:

HSTC:PMC's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.865
* Ranked among companies with meaningful ROE % only.

Pharmedic Pharmaceutical Medicinal Joint Stock Company  (HSTC:PMC) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=( / )*( / )*( / )
=Net Margin %*Asset Turnover*Equity Multiplier
= %**
=ROA %*Equity Multiplier
= %*
= %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= ( / ) * ( / ) * ( / ) * ( / ) * ( / )
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= * * % * *
= %

Note: The net income data used here is four times the quarterly (. 20) net income data. The Revenue data used here is four times the quarterly (. 20) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.

Pharmedic Pharmaceutical Medicinal Joint Stock Company ROE % Related Terms

Pharmedic Pharmaceutical Medicinal Joint Stock Company ROE % Historical Data

* Premium members only.

The historical data trend for Pharmedic Pharmaceutical Medicinal Joint Stock Company's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmedic Pharmaceutical Medicinal Joint Stock Company ROE % Chart

Pharmedic Pharmaceutical Medicinal Joint Stock Company Annual Data
Trend
ROE %

Pharmedic Pharmaceutical Medicinal Joint Stock Company Quarterly Data
ROE %

HSTC:PMC vs IMNPQ: ROE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Pharmedic Pharmaceutical Medicinal Joint Stock Company's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharmedic Pharmaceutical Medicinal Joint Stock Company ROE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Pharmedic Pharmaceutical Medicinal Joint Stock Company's ROE % distribution charts can be found below:

* The bar in red indicates where Pharmedic Pharmaceutical Medicinal Joint Stock Company's ROE % falls into.


Pharmedic Pharmaceutical Medicinal Joint Stock Company ROE % Calculation

Pharmedic Pharmaceutical Medicinal Joint Stock Company's annualized ROE % for the fiscal year that ended in . 20 is calculated as

ROE %=Net Income (A: . 20 )/( (Total Stockholders Equity (A: . 20 )+Total Stockholders Equity (A: . 20 ))/ count )
=/( (+)/ )
=/
= %

Pharmedic Pharmaceutical Medicinal Joint Stock Company's annualized ROE % for the quarter that ended in . 20 is calculated as

ROE %=Net Income (Q: . 20 )/( (Total Stockholders Equity (Q: . 20 )+Total Stockholders Equity (Q: . 20 ))/ count )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (. 20) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) has a ROE % of 0.00% as of . 20. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pharmedic Pharmaceutical Medicinal Joint Stock Company and its competitors.
Is Pharmedic Pharmaceutical Medicinal Joint Stock Company's ROE % too high?
Pharmedic Pharmaceutical Medicinal Joint Stock Company's current ROE % is 0.00%.
How does Pharmedic Pharmaceutical Medicinal Joint Stock Company's ROE % compare to IMNPQ?
Pharmedic Pharmaceutical Medicinal Joint Stock Company's ROE % of 0.00% can be compared against companies in the Drug Manufacturers industry. The industry median ROE % is 5.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Pharmedic Pharmaceutical Medicinal Joint Stock Company and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmedic Pharmaceutical Medicinal Joint Stock Company's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmedic Pharmaceutical Medicinal Joint Stock Company stock overvalued right now?
Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC) has a current ROE % of 0.00%. The current ROE % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Pharmedic Pharmaceutical Medicinal Joint Stock Company (HSTC:PMC), the current ROE % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharmedic Pharmaceutical Medicinal Joint Stock Company Business Description

Address 367 Nguyen Trai, Nguyen Cu Trinh Ward, District 1, TP. HCM, Ho Chi Minh, VNM
Pharmedic Pharmaceutical Medicinal Joint Stock Company is involved in the production and sales of pharmaceutical products, cosmetics, medical supplies, and other products in the health sector. The company's products include Farzincol Bottle, Farzincol Syrup, Sibemag, Vitamin C 50, Vitamin PP 500, Vitamin PP 50, Nacofar, Cooldrop, Inhaler, Povidine 10% 90ml, Povidine 4% 500, Povidine 10% 8ml, and Povidine 4% 800.